Search - tctmd.com

Displaying 81 - 100 of 273

Sort: Relevancy | Date

Presentation TCT 2016

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

Presenter: Neil E. Moat, John G. Webb, Alexandra J. Lansky

October 31, 2016

Presentation TCT 2016

ACT I Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Klaus D. Mathias

October 31, 2016

Presentation TCT 2016

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

Presenter: William A. Gray, Stephan Windecker, Kenneth Rosenfield

October 31, 2016

Presentation TCT 2016

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

Presenter: Neil E. Moat, John G. Webb, Adam B. Greenbaum

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Severe Calcified Lesion

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Juying Qian

October 31, 2016

Presentation TCT 2016

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

Presenter: Neil E. Moat, John G. Webb, Stephen R. Ramee

October 31, 2016

Presentation TCT 2016

CTSN Severe MR 2-Year Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Patrick M. McCarthy

October 31, 2016

Presentation TCT 2016

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Presenter: Neil E. Moat, John G. Webb, Pieter R. Stella

October 31, 2016

Presentation TCT 2016

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Presenter: William A. Gray, Stephan Windecker, Michael Argenziano

October 31, 2016

Presentation TCT 2016

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

Presenter: Neil E. Moat, John G. Webb, Eric Van Belle

October 31, 2016

Presentation TCT 2016

EFS in the USA: Challenges and Developments (An Investigators Perspective)

Presenter: Andrew Farb, Aaron V. Kaplan, Martin B. Leon

October 31, 2016

Presentation TCT 2016

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

Presenter: Neil E. Moat, John G. Webb, Scott Lim

October 31, 2016

Presentation TCT 2016

2016 Treatment of Saphenous Vein Grafts, Including Management of Acute Occlusions

Presenter: Jonathan M. Hill, Dimitri Karmpaliotis, Joseph P. Carrozza Jr

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Early Feasibility Studies in the USA: Early Example With Success

Presenter: Andrew Farb, Aaron V. Kaplan, Steven R. Bailey

October 31, 2016

Presentation TCT 2016

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Presenter: Neil E. Moat, John G. Webb, Jeffrey J. Popma

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

Early Feasibility Studies in USA: Progress Report From the FDA

Presenter: Andrew Farb, Aaron V. Kaplan, Carla M Wiese

October 31, 2016

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

Presentation TCT 2016

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Presenter: Raj Makkar, Lars Sondergaard, Luis Nombela-Franco

October 31, 2016

Advertisement

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

ACT I Critique: Pro and Con

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

My Most Challenging Case 2016: Severe Calcified Lesion

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

CTSN Severe MR 2-Year Critique: Pro and Con

The ELECT Trial: A Randomized Evaluation of Periprosthetic Regurgitation After TAVI With Sapien 3 or CoreValve Using Mulit-Modality Imaging

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Von Willebrand Factor Multimers During TAVR: Implications for Treatment of Para-Valvular Regurgitation

EFS in the USA: Challenges and Developments (An Investigators Perspective)

A Practical Algorithm for Managing Para-Valvular Regurgitation After TAVR

2016 Treatment of Saphenous Vein Grafts, Including Management of Acute Occlusions

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Early Feasibility Studies in the USA: Early Example With Success

Complications 1. Para-Valvular Regurgitation: Should Mild Para-Valvular Regurgitation After TAVR Be Treated?

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Early Feasibility Studies in USA: Progress Report From the FDA

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Controversy 5. Adjunctive Pharmacotherapy for TAVR: Real World Usage Patterns of Antiplatelet and Antithrombotic Agents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content